Outpace Bio, a Seattle-based startup using AI to design proteins for cancer therapies targeting solid tumors, has secured $144 million in new funding from investors. Outpace will utilize this funding to test its treatment in a clinical setting to confirm its approach to combating cancer.
Co-founders Marc Lajoie and Scott Boyken met as postdoctoral fellows at the University of Washington’s Institute for Protein Design (IPD), which has an impressive record of producing biotech startups. With a total of $200 million raised to date, Outpace Bio is one of several homegrown startups emerging from Washington state’s premier research institutions.